ijms-logo

Journal Browser

Journal Browser

Positive and Negative Determinants of Ischaemic Injury—Co-morbidities and Cardioprotection 2020

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 5675

Special Issue Editor


E-Mail Website
Guest Editor
School of Pharmacy and Medical Science, Griffith University, Southport, QLD 4217, Australia
Interests: ischemia-reperfusion; cardioprotection; infarction; co-morbidities
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Ischaemic heart disease and associated heart attack (acute myocardial infarction, AMI), together with subsequent heart failure are the lead causes of death worldwide, presenting a profound healthcare burden. There is thus a great need for adjunctive protective therapy that can be applied prior to, with or after reperfusion to improve both short and longer term outcomes from AMI (or surgical ischaemia), and extend the effective window for reperfusion. Thus far, no adjunctive treatment has been developed that is effective in the context of the co-morbidities associated with ischaemic heart disease. Processes of, and outcomes from cardiac ischaemia-reperfusion injury are influenced by multiple factors, including comorbidities (such as diabetes, obesity, hypertension etc), sex, age and other gene and phenotypic features. The long-running and unmet challenge of cardioprotection can only be met through consideration of these critical positive and negative determinants of outcome.

This Special Issue, “Positive and Negative Determinants of Ischaemic Injury – Co-Morbidities and Cardioprotection” will focus on novel, emerging paradigms from the study (original research articles or reviews) around the current understanding of the effects of comorbid conditions on myocardial ischaemia-reperfusion processes, the influences on cardioprotective signalling and outcomes, and novel strategies for protecting the heart from accidental and surgical I-R.

Prof. Dr. Jason Peart
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Ischaemia-reperfusion
  • Precondtioning
  • Postconditioning
  • Cardioprotection
  • Cell signaling
  • Age
  • Diabetes
  • Obesity
  • Hypercholesterolaemia
  • Hypertrophy
  • Chronic Diseases
  • Receptor Signaling

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1534 KiB  
Article
Nourin-Associated miRNAs: Novel Inflammatory Monitoring Markers for Cyclocreatine Phosphate Therapy in Heart Failure
by Salwa A. Elgebaly, Robert Todd, Donald L. Kreutzer, Robert Christenson, Nashwa El-Khazragy, Reem K. Arafa, Mostafa A. Rabie, Ahmed F. Mohamed, Lamiaa A. Ahmed and Nesrine S. El Sayed
Int. J. Mol. Sci. 2021, 22(7), 3575; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073575 - 30 Mar 2021
Cited by 4 | Viewed by 3126
Abstract
Background: Cyclocreatine phosphate (CCrP) is a potent bioenergetic cardioprotective compound known to preserve high levels of cellular adenosine triphosphate during ischemia. Using the standard Isoproterenol (ISO) rat model of heart failure (HF), we recently demonstrated that the administration of CCrP prevented the development [...] Read more.
Background: Cyclocreatine phosphate (CCrP) is a potent bioenergetic cardioprotective compound known to preserve high levels of cellular adenosine triphosphate during ischemia. Using the standard Isoproterenol (ISO) rat model of heart failure (HF), we recently demonstrated that the administration of CCrP prevented the development of HF by markedly reducing cardiac remodeling (fibrosis and collagen deposition) and maintaining normal ejection fraction and heart weight, as well as physical activity. The novel inflammatory mediator, Nourin is a 3-KDa formyl peptide rapidly released by ischemic myocardium and is associated with post-ischemic cardiac inflammation. We reported that the Nourin-associated miR-137 (marker of cell damage) and miR-106b-5p (marker of inflammation) are significantly upregulated in unstable angina patients and patients with acute myocardial infarction, but not in healthy subjects. Objectives: To test the hypothesis that Nourin-associated miR-137 and miR-106b-5p are upregulated in ISO-induced “HF rats” and that the administration of CCrP prevents myocardial injury (MI) and reduces Nourin gene expression in “non-HF rats”. Methods: 25 male Wistar rats (180–220 g) were used: ISO/saline (n = 6), ISO/CCrP (0.8 g/kg/day) (n = 5), control/saline (n = 5), and control/CCrP (0.8 g/kg/day) (n = 4). In a limited study, CCrP at a lower dose of 0.4 g/kg/day (n = 3) and a higher dose of 1.2 g/kg/day (n = 2) were also tested. The Rats were injected SC with ISO for two consecutive days at doses of 85 and 170 mg/kg/day, respectively, then allowed to survive for an additional two weeks. CCrP and saline were injected IP (1 mL) 24 h and 1 h before first ISO administration, then daily for two weeks. Serum CK-MB (U/L) was measured 24 h after the second ISO injection to confirm myocardial injury. After 14 days, gene expression levels of miR-137 and miR-106b-5p were measured in serum samples using quantitative real-time PCR (qPCR). Results: While high levels of CK-MB were detected after 24 h in the ISO/saline rats indicative of MI, the ISO/CCrP rats showed normal CK-MB levels, supporting prevention of MI by CCrP. After 14 days, gene expression profiles showed significant upregulation of miR-137 and miR-106b-5p by 8.6-fold and 8.7-fold increase, respectively, in the ISO/saline rats, “HF rats,” compared to the control/saline group. On the contrary, CCrP treatment at 0.8 g/kg/day markedly reduced gene expression of miR-137 by 75% and of miR-106b-5p by 44% in the ISO/CCrP rats, “non-HF rats,” compared to the ISO/Saline rats, “HF rats.” Additionally, healthy rats treated with CCrP for 14 days showed no toxicity in heart, liver, and renal function. Conclusions: Results suggest a role of Nourin-associated miR-137 and miR-106b-5p in the pathogenesis of HF and that CCrP treatment prevented ischemic injury in “non-HF rats” and significantly reduced Nourin gene expression levels in a dose–response manner. The Nourin gene-based mRNAs may, therefore, potentially be used as monitoring markers of drug therapy response in HF, and CCrP—as a novel preventive therapy of HF due to ischemia. Full article
Show Figures

Figure 1

13 pages, 2566 KiB  
Article
Cardioprotection via Metabolism for Rat Heart Preservation Using the High-Pressure Gaseous Mixture of Carbon Monoxide and Oxygen
by Chiharu Suzuki, Naoyuki Hatayama, Tadashi Ogawa, Eri Nanizawa, Shun Otsuka, Koichiro Hata, Hiroshi Seno, Munekazu Naito and Shuichi Hirai
Int. J. Mol. Sci. 2020, 21(22), 8858; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21228858 - 23 Nov 2020
Cited by 9 | Viewed by 2102
Abstract
The high-pressure gas (HPG) method with carbon monoxide (CO) and oxygen (O2) mixture maintains the preserved rat heart function. The metabolites of rat hearts preserved using the HPG method (HPG group) and cold storage (CS) method (CS group) by immersion in [...] Read more.
The high-pressure gas (HPG) method with carbon monoxide (CO) and oxygen (O2) mixture maintains the preserved rat heart function. The metabolites of rat hearts preserved using the HPG method (HPG group) and cold storage (CS) method (CS group) by immersion in a stock solution for 24 h were assessed to confirm CO and O2 effects. Lactic acid was significantly lower and citric acid was significantly higher in the HPG group than in the CS group. Moreover, adenosine triphosphate (ATP) levels as well as some pentose phosphate pathway (PPP) metabolites and reduced nicotinamide adenine dinucleotide phosphate (NADPH) were significantly higher in the HPG group than in the CS group. Additionally, reduced glutathione (GSH), which protects cells from oxidative stress, was also significantly higher in the HPG group than in the CS group. These results indicated that each gas, CO and O2, induced the shift from anaerobic to aerobic metabolism, maintaining the energy of ischemic preserved organs, shifting the glucose utilization from glycolysis toward PPP, and reducing oxidative stress. Both CO and O2 in the HPG method have important effects on the ATP supply and decrease oxidative stress for preventing ischemic injury. The HPG method may be useful for clinical application. Full article
Show Figures

Figure 1

Back to TopTop